Needham Reiterates Hold on Sage Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Hold rating on Sage Therapeutics (NASDAQ:SAGE).
July 24, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Needham analyst Ami Fadia has reiterated a Hold rating on Sage Therapeutics. This suggests that the analyst does not see a significant upside or downside in the near term.
The Hold rating indicates that the analyst believes the stock is fairly valued at its current price. This typically suggests limited short-term price movement, either up or down.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100